Ligand id: 2693

Name: troglitazone

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 110.16
Molecular weight 441.16
XLogP 3.52
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Troglitazone is used to treat non-insulin-dependent diabetes mellitus (type II diabetes), along with diet and exercise. Treatment may also include insulin, a sulfonylurea drug, or metformin if necessary. However, use of this drug has been withdrawn in the UK, US and Japan due to adverse liver effects associated with its use.
Mechanism Of Action and Pharmacodynamic Effects
Troglitazone is an agonist with affinity for PPARγ and to a lesser extent PPARα. Activation of PPARs by troglitazone results in decreased NFκB, which reduces inflammation by regulating genes involved in the immune response.